Cystic Fibrosis Trial, Recruiting NCT07102043 Sponsor: University of Alabama at Birmingham Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Cystic Fibrosis Trial, Recruiting

NCT07102043
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Cystic Fibrosis Related Diabetes (CFRD)
  • People aged between 21 and 75 years old at the time of signing the consent form
  • People with a body mass index (a measure of body weight relative to height) between 19 and 50, or between 17 and 48 for people of Asian background
  • People whose kidneys are functioning within certain levels, based on a blood marker called creatinine (below 1.4 for women and 1.5 for men — confirm with trial site)
  • People whose blood sugar levels over the past few months (measured by a test called HbA1c) are at or below 11%, whether managed through lifestyle, tablets, or insulin (including insulin pumps or multiple daily injections)
  • People who are taking a cystic fibrosis medication called ETI (elexacaftor/tezacaftor/ivacaftor) at the full dose approved by the FDA
  • People who are willing to keep their weight stable for the whole duration of the study
  • People who understand the study requirements and are willing to follow the study plan and sign the consent form

Who may not be able to join:

  • People who have a severe or debilitating long-term illness (other than the condition being studied)
  • People with low red blood cell levels (anaemia) — below a certain level in both men and women (confirm with trial site)
  • People who have unexplained symptoms of an undiagnosed illness at the time of joining
  • People who currently misuse alcohol or recreational drugs
  • People who are pregnant
  • People with active liver disease or significant liver scarring (people with only mildly elevated liver readings may still be considered — confirm with trial site)
  • People currently taking any of the following medications: corticosteroids (such as prednisone), benzodiazepines (such as diazepam), opioid pain medicines, barbiturates, blood thinners (anticoagulants), or any other medication the trial doctor considers to be a safety concern

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rita Basu, MD, UAB Medicine

Phone: 205-934-1200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
28 May 2026
Est. completion
1 May 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Disposition Index in CFRD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov